Sandoz Group AG: The Off-Patent Biopharmaceutical Giant's Independence Play

I. Introduction & The Sandoz Paradox

At 9:00 a.m. on October 4, 2023, a ticker symbol dormant for twenty-seven years reappeared on the SIX Swiss Exchange. The symbol was SDZ, representing Sandoz Group AG, which Novartis had just spun off to its shareholders as a dividend-in-kind—distributing one Sandoz share for every five Novartis shares owned, with no cash raised, no bookrunners, and no traditional roadshow.¹ The stock opened at CHF 24.00, giving the newly independent company an initial equity valuation of roughly CHF 10.3 billion.²³

Spinoffs conducted without an initial public offering rarely generate headlines, yet they frequently reshape billions of dollars in enterprise value. In Sandoz's case, there was no traditional opening bell or public equity sale. Novartis simply separated its generics and biosimilars division into a standalone entity and left public markets to determine its value.

The market's initial verdict was muted. With an equity valuation of CHF 10.3 billion against roughly $9.6 billion in net sales, Sandoz debuted at a multiple suggesting investors viewed it much as it had functioned within Novartis: a slow-growing, capital-intensive manufacturer of low-margin commodity drugs subject to persistent price deflation. In its first full year as an independent company, Sandoz reported a core EBITDA margin of 18.1%—respectable for generic pharmaceuticals, but unremarkable relative to the broader healthcare sector.⁴

Nearly three years later, on August 5, 2026, Sandoz reported first-half results, sending its stock up as much as 8.1% intraday to CHF 69.46.⁵ Its market valuation had nearly tripled from its debut, reflecting a fundamental shift in how investors appraised the business.

The Sandoz paradox centers on an operational and strategic transformation: how does a 140-year-old Basel chemical enterprise—which originated producing synthetic dyes along the Rhine, developed breakthrough pharmaceuticals like ergotamine and LSD, and was later absorbed in what was then history's largest corporate merger—reposition itself as a high-barrier biologics manufacturer while decoupling twenty-seven years of integrated IT infrastructure, manufacturing facilities, procurement contracts, and personnel?

The core thesis to test rests on a stark structural difference in pharmaceutical manufacturing. Small-molecule generics—the pills, capsules, and creams that replicate chemically synthesized drugs—operate in a high-volume, price-deflating market. Low technical barriers allow widespread competition, while in the United States, three major purchasing alliances command the market and force annual price reductions. Biosimilars, by contrast, present far higher barriers to entry. As complex copies of biologic medicines grown in living cells, they require hundreds of millions of dollars and nearly a decade to develop, followed by extensive patent litigation. Because fewer competitors can enter the market, biosimilar prices erode more gradually and from a significantly higher starting point.

Management's strategy assumes that altering the product mix—increasing the proportion of higher-margin biosimilars while reducing reliance on commodity small-molecule drugs—can raise group core EBITDA margins from 18.1% to between 24% and 26% by 2028.⁶ This is an ambitious target: expanding margins by six to eight percentage points over five years requires driving group profitability higher even as Sandoz's largest revenue segment contracts in real terms.

Early execution supports this trajectory: core EBITDA margin reached 20.1% in 2024, 21.7% in 2025, and 20.9% in the first half of 2026, with management projecting roughly 100 basis points of full-year expansion.⁷⁴⁸ However, initial margin gains do not guarantee long-term execution. The second phase of margin expansion will be harder to achieve, as initial cost savings—such as rationalizing unprofitable product lines and eliminating corporate overhead allocations from Novartis—are one-time benefits.

This narrative examines how Sandoz constructed that transformation. The company's trajectory spans its origin as a nineteenth-century dye producer in Basel, its absorption in a mega-merger that temporarily erased its corporate identity, an aggressive generics acquisition strategy executed near market peaks, and a failed asset sale blocked by the U.S. Federal Trade Commission. It culminates in Sandoz launching the first FDA-approved biosimilar in the United States and facing intense present-day competition from nimble Korean manufacturers with lower cost structures.

↑ Back to Top

II. Origins: Dye Stuffs, Ergot Alkaloids, and the LSD Epoch (1886–1996)

On July 1, 1886, chemists Alfred Kern, thirty-six, and Edouard Sandoz, thirty-three, established a partnership on 11,000 square meters of land along the Rhine in Basel. Kern brought technical experience from various Swiss chemical ventures, while Sandoz provided commercial direction. Operating as Kern & Sandoz, they began manufacturing synthetic dyes, including alizarin blue and auramine, for the European textile trade.⁹

The nature of 1880s dye manufacturing explains the origin of many modern European pharmaceutical majors. Synthetic dye production was the first scalable industrial chemistry, converting coal tar derivatives into complex organic molecules. The technical discipline required to control reactions at scale, purify compounds, and characterize molecular structures directly matched the capabilities needed to produce medicines. Situated at the crossroads of Swiss capital, German chemical expertise, and Rhine River shipping, Basel developed the world's densest concentration of chemical talent, giving rise to firms including Ciba, Geigy, and Hoffmann-La Roche.

Following Kern's death in 1893, Sandoz recruited chemist Robert Gnehm and initiated a strategic shift from textile dyes toward therapeutic compounds. Within a decade, the enterprise produced antipyrine, a fever reducer, completing its transition into pharmaceuticals.⁹

During the twentieth century, Sandoz established its core scientific franchise in ergot alkaloids—compounds derived from a rye fungus with potent effects on vascular and nervous systems. Through a systematic research program isolating and modifying these molecules, Sandoz developed ergotamine, a foundational migraine therapy, alongside derivatives for obstetric and circulatory applications. The effort established an early model for structured pharmaceutical research platforms.

That research platform also yielded one of the most culturally significant discoveries in pharmaceutical history. On November 16, 1938, Sandoz chemist Albert Hofmann synthesized lysergic acid diethylamide (LSD-25) while investigating circulatory and respiratory stimulants. Initial testing on animals showed little therapeutic promise beyond mild restlessness, leading the company to shelve the compound.¹⁰ On April 16, 1943, Hofmann re-examined the molecule, accidentally absorbing a trace quantity and experiencing intense psychoactive effects. Three days later, he deliberately ingested 250 micrograms and experienced the full effects during a bicycle ride through Basel—an event later remembered as "Bicycle Day."¹¹

Sandoz commercialized the substance in 1947, marketing LSD to psychiatric researchers under the trade name Delysid. For two decades, Delysid served as an experimental tool distributed to academic institutions and hospitals.¹¹ However, as the drug spread beyond clinical settings and became central to 1960s counterculture, Sandoz withdrew it from the market—an early example of a drug manufacturer losing control over a compound's societal use.

The remainder of the twentieth century was marked by industrial consolidation. Sandoz expanded into a global conglomerate encompassing pharmaceuticals, agrochemicals, nutrition, and specialty chemicals. It grew alongside its Basel rivals Ciba and Geigy, which had merged in 1970 to form Ciba-Geigy.

On March 7, 1996, Ciba-Geigy and Sandoz announced a $27 billion merger to create Novartis, which stood at the time as the largest corporate combination in history.¹²¹³ The transaction closed in December 1996, retiring the 110-year-old Sandoz brand name.

This early history established a recurring strategic pattern. Sandoz developed technical franchises—first in ergot alkaloids during the twentieth century and later in biosimilars in the twenty-first—by mastering complex chemistry and biology that competitors avoided. Yet it was twice absorbed into larger corporate structures with differing strategic priorities. The fundamental question for Sandoz's modern era is whether corporate independence enables it to break that historical pattern.

↑ Back to Top

III. The Novartis Era: Building a Generic Roll-Up and the M&A Trap (1996–2017)

Seven years after retiring the brand following the Ciba-Geigy merger, Novartis revived the Sandoz name.

In 2003, the group consolidated its scattered generic-medicine subsidiaries—a patchwork of regional operations built or acquired over decades under a dozen local brand names—under the unified Sandoz umbrella. The rebrand served a practical commercial purpose: a generic drug division requires credibility with hospital procurement committees and national health authorities rather than consumer brand recognition, and the Sandoz name retained more than a century of Basel manufacturing reputation.

Novartis then embarked on an aggressive acquisition drive to build operational scale, initiating a strategy that demonstrated both the power and the structural limits of generic drug roll-ups.

The roll-up years

On February 21, 2005, Novartis announced it would acquire 100% of German generics leader Hexal AG and a controlling stake in U.S.-listed Eon Labs for a combined EUR 5.65 billion in cash.¹⁴ Hexal ranked as the second-largest generics producer in Germany with an established European footprint, while Eon was a rapidly growing American operator with an existing partnership with Hexal. Novartis completed the Hexal purchase in June 2005 and the Eon tender offer in July.¹⁵

The underlying thesis rested on scale, and the immediate result proved dramatic: the combination vaulted Sandoz past Israel's Teva to make it, briefly, the largest generics manufacturer in the world.¹⁵ Teva reclaimed top ranking the following year by acquiring Ivax, and the two rivals repeatedly exchanged leadership over the next decade. The dynamic highlighted a core reality of the generics industry: market leadership was rented rather than owned, easily reallocated to whichever competitor executed the next major acquisition.

Seven years later, Sandoz expanded its portfolio again. On May 2, 2012, it agreed to buy Fougera Pharmaceuticals—a U.S. specialty dermatology generics maker owned by a private-equity consortium led by Nordic Capital—for $1.525 billion in cash, closing that July.¹⁶¹⁷ The combined dermatology franchise generated roughly $620 million in annual sales, concentrated heavily in the United States, establishing Sandoz as the world's largest generic dermatology company.¹⁶

What the deals actually bought

A closer examination of the Fougera transaction highlights the valuation dynamics of the era. Paying $1.525 billion to anchor a business contributing to a roughly $620 million franchise implied a valuation multiple near 2.5 times sales for topical creams and ointments—products whose competitive moat derived from specialized formulation and manufacturing complexity rather than long-term patent protection. This represented a full price for an asset class where technical entry barriers, though real, remained finite.

Both the Hexal-Eon and Fougera acquisitions shared a structural vulnerability that was obscured at signing but evident a decade later: they were bets that U.S. small-molecule generic prices would hold steady. Novartis acquired scale in oral solid doses and topicals at the exact moment American drug purchasers were consolidating into powerful alliances that stripped manufacturers of pricing power.

The acquisitions illustrate a central lesson of commoditized markets. Building scale in a standardized product category assumes that size confers pricing power. While scale provides cost efficiency, cost advantages in a market dominated by three consolidated buying groups are quickly competed away through price reductions. Manufacturers end up operating larger, more efficient factories while product prices decline faster than unit production costs.

The conglomerate subsidy trap

A second structural challenge was internal, creating the capital allocation friction that ultimately justified the 2023 spinoff.

Within Novartis, Sandoz functioned as the high-volume engine. It generated reliable cash flow, supported an extensive European manufacturing footprint, and provided market reach in distribution channels that the innovative pharmaceuticals division did not touch. What it could not do was win capital allocation arguments.

Throughout the 2010s, Novartis's capital allocation committee faced starkly contrasting options. Investing an incremental dollar into a biosimilar development program required seven to nine years of work, a large clinical trial program, and complex patent litigation, with ultimate gross margins in the 60% range. Alternatively, directing that dollar into patent-protected innovative medicines like Entresto, Cosentyx, or Zolgensma yielded gross margins above 85%, multi-billion-dollar peak sales potential, and direct alignment with the parent company's strategic identity.

From a portfolio management perspective, prioritizing innovative therapeutics was entirely logical. However, this dynamic meant that for roughly fifteen years, high-return opportunities within Sandoz were systematically constrained by even higher-return alternatives elsewhere in the organization.

This situation demonstrated the classic conglomerate subsidy trap: a business division is not underfunded because it is underperforming, but because it sits alongside higher-margin corporate priorities. Resolving the constraint required establishing Sandoz as an independent entity, allowing its capital to be priced against its own opportunity set rather than that of a novel drug innovator.

By the mid-2010s, however, an even more urgent challenge was emerging from the American market—arriving faster than Sandoz leadership had anticipated.

↑ Back to Top

IV. The Generic Price Cliff and the Failed Aurobindo Fire Sale (2018–2020)

By 2015, the traditional economic model governing U.S. generic pharmaceuticals began to unravel.

For decades, the arithmetic of American generics had remained predictable: annual price erosion stayed in the mid-single digits, volume growth offset price declines, and new product launches continually replenished earnings. But within a few years, annual price declines accelerated into the 10% to 15% range—and in certain high-volume categories, fell even faster—without stabilizing.

The driver of this shift was structural. Between 2013 and 2016, major U.S. drug buyers consolidated into three purchasing alliances: Red Oak Sourcing (CVS Health and Cardinal Health), ClarusONE (Walmart and McKesson), and Walgreens Boots Alliance Development. Together, these three consortiums controlled the vast majority of retail generic purchasing volume in the United States. Almost overnight, a fragmented market of drug manufacturers faced a concentrated group of three dominant buyers.

The market dynamics proved relentless. When multiple manufacturers produce identical bioequivalent tablets and three consortiums command shelf access, buyers conduct reverse auctions that force producers toward marginal cost. Neither manufacturing scale nor high production standards offered pricing power, because bioequivalence serves as a binary regulatory threshold rather than a point of commercial differentiation. For generic producers, survival required either shifting to complex, high-barrier formulations or exiting commodity markets altogether.

The exit that wasn't

Novartis initially chose to exit. In September 2018, it agreed to sell Sandoz's U.S. generic oral solids and dermatology portfolio—encompassing the legacy Fougera assets along with its oral tablet business—to Indian manufacturer Aurobindo Pharma in a transaction valued at approximately $1 billion.¹⁸

Strategic logic aligned for both parties. Aurobindo possessed a low-cost manufacturing footprint in India and the scale necessary to operate in a deflating U.S. retail market, while Novartis aimed to divest its most price-sensitive operations and redeploy capital into higher-margin innovator drugs.

However, the transaction stalled during regulatory review. Over the subsequent eighteen months, the U.S. Federal Trade Commission evaluated overlapping product portfolios between the two producers amid heightened scrutiny over generic market concentration and ongoing industry-wide antitrust investigations into generic price-fixing.

On April 2, 2020, Novartis and Aurobindo announced that they had mutually agreed to terminate the deal, stating that FTC approval had not been obtained within anticipated timelines.¹⁹ There was no break fee.²⁰ Consequently, Novartis retained ownership of a division it had spent eighteen months attempting to divest.

The consolation prize

The transaction's termination initially left Sandoz in a difficult position. The company retained a U.S. small-molecule franchise that management had explicitly declared non-core, while operating margins continued to face downward pressure. However, executive leadership had already begun to shift. In 2019, Richard Saynor assumed the role of CEO at Sandoz, bringing extensive experience managing mature, off-patent pharmaceutical portfolios at GSK and Teva.

Rather than seeking another buyer, Saynor initiated an operational restructuring centered on three strategic pillars.

First, Sandoz systematically exited unprofitable commodity markets. Instead of defending market share in commoditized oral solids, management pruned product lines that failed to clear profitability thresholds, accepting top-line volume declines to protect overall margins.

Second, the company reallocated capital toward high-barrier complex medicines. Resources previously dedicated to defending commodity generics were redirected into biosimilars, where technical and clinical hurdles limited competitive entry and slowed price erosion.

Third, Sandoz repurposed its European manufacturing footprint into a strategic asset. While European production incurred higher operating costs relative to Asian manufacturing hubs, maintaining regional facilities offered supply-chain security—a capability that gained significant value as COVID-19 pandemic disruptions highlighted global antibiotic shortages and supply dependencies.

Ultimately, the failed Aurobindo transaction forced a strategic pivot that a successful divestment might have delayed. Rather than monetizing the asset and shrinking its generic footprint, Sandoz was compelled to restructure its product mix around higher-margin biosimilars and complex formulations—establishing the operational foundation required for its eventual independence from Novartis.

↑ Back to Top

V. The Great Pivot: Pioneering Biosimilars and the October 2023 Spin-Off

Understanding why biosimilars represent a fundamentally different economic model from traditional generics requires examining the structural gap between chemical synthesis and biological manufacturing.

A small-molecule drug features a fixed, defined chemical structure. Once that structure is known, a manufacturer can synthesize the compound, verify chemical identity, demonstrate bioequivalence in a small cohort of healthy volunteers, and submit an abbreviated regulatory application. Development typically costs single-digit millions of dollars, centered on a straightforward regulatory question: whether the synthesized molecule is identical to the reference drug.

A biologic, by contrast, is a complex protein produced inside living cells. Its identity depends not only on its primary amino acid sequence, but also on cellular folding, glycosylation patterns, and purification protocols. Any modification to cell lines, growth media, temperature, or purification resins alters the final product. Consequently, manufacturers cannot simply replicate the molecule; they must independently engineer a cell line to produce a functionally equivalent protein, then prove biosimilarity through extensive analytical characterization and comparative clinical trials. Development expenses frequently reach hundreds of millions of dollars over nearly a decade, followed by complex litigation against originators defending dense patent thickets.

This structural cost barrier creates a natural competitive moat. It also explains why biosimilar prices decline more gradually than small-molecule generics: entering a market with four competitors rather than fourteen yields far less aggressive price erosion during market auctions.

Sandoz got there first, twice

Sandoz built its position in biosimilars by pioneering regulatory approval pathways in both Europe and the United States.

On April 12, 2006, the European Medicines Agency approved Omnitrope, a biosimilar recombinant human growth hormone referencing Genotropin, making it the first biosimilar authorized in a major regulated market.²¹ Europe established a biosimilar regulatory framework well ahead of the U.S., and Sandoz served as the initial test case for the new regulatory pathway.

Nine years later, the company achieved a similar milestone in the United States. On March 6, 2015, the U.S. Food and Drug Administration approved Zarxio (filgrastim-sndz), a biosimilar referencing Amgen's Neupogen, as the first biosimilar authorized under the Biologics Price Competition and Innovation Act.²² Following litigation with Amgen, Sandoz launched Zarxio in September 2015.²³ To support its U.S. filing, Sandoz leveraged more than 7.5 million patient-days of European clinical exposure with the product, demonstrating how early European experience could accelerate U.S. market entry.

First-mover status provided tangible advantages, though with distinct strategic limits. Early regulatory navigation built institutional expertise in review procedures, established working relationships with regulatory bodies, and refined internal analytics—capabilities that compress development timelines rather than block competing entrants.

The patent cliff that made it worth doing

The commercial expansion of biosimilars was driven by an unprecedented wave of patent expirations across major biologic therapeutics. Blockbuster drugs introduced in the 1990s and 2000s—including Humira (adalimumab), Stelara (ustekinumab), Eylea (aflibercept), Tysabri (natalizumab), Prolia and Xgeva (denosumab), and Soliris (eculizumab)—faced loss of exclusivity within a compressed timeframe, exposing more than $100 billion in annual originator revenues to off-patent competition.

Sandoz targeted this opportunity with a specialized biosimilar portfolio. Key products included Hyrimoz (referencing adalimumab); Tyruko (referencing natalizumab), which received FDA approval on August 24, 2023, as the first biosimilar natalizumab;²⁴ Pyzchiva (referencing ustekinumab), approved on July 1, 2024;²⁵ Enzeevu (referencing aflibercept in the U.S.) alongside its European counterpart Afqlir; and Wyost and Jubbonti (referencing denosumab).

Rather than relying solely on internal R&D, Sandoz assembled this pipeline through a hybrid model of in-house development, strategic licensing, and targeted acquisitions. For example, Pyzchiva originated from a September 2023 partnership with Samsung Bioepis, under which Samsung Bioepis managed development while Sandoz secured commercialization rights in key markets.²⁶ Sandoz similarly acquired commercial assets such as Cimerli to expand its product breadth. This strategy established Sandoz as a global commercialization platform for off-patent biologics as much as a direct developer—a distinction that carries different margin profiles and partnership dependencies.

The separation

Novartis finalized the spin-off parameters on September 25, 2023, and executed the transaction on October 4.²⁷¹ The separation involved no capital raise or public equity offering; instead, shares were distributed directly to existing Novartis equity holders as a tax-neutral dividend-in-kind.

Choosing a direct spin-off over an initial public offering reflected strategic market positioning. A traditional IPO would have forced Novartis to market the equity during a period of depressed valuations for generic drugmakers. A dividend-in-kind bypassed immediate price discovery, leaving market valuation to secondary trading as Sandoz established its operational performance. However, this structure placed a large volume of stock with index funds and institutional investors focused primarily on innovative pharmaceuticals, resulting in predictable early selling pressure that weighed on the shares during their initial trading sessions.

The umbilical cord

Beyond portfolio strategy, corporate independence required unwinding twenty-seven years of shared operational infrastructure. Operating within Novartis meant Sandoz shared enterprise resource planning systems, treasury management, quality control protocols, procurement agreements, distribution networks, regulatory filings, real estate, and IT networks with its parent company. Establishing independent operations required deploying hundreds of standalone systems and renegotiating thousands of commercial contracts while maintaining uninterrupted drug supplies.

The financial cost of this operational uncoupling was substantial. One-off separation and transformation expenses peaked at approximately $700 million in 2024, decreased to around $400 million in 2025, and were projected at roughly $300 million for 2026.⁴ For the first half of 2026, management reported underlying one-off separation costs of €142 million and reaffirmed its full-year run rate expectation of approximately €300 million, signaling that the separation process was nearing completion.⁸

This downward trajectory in separation expenses directly impacts cash flow interpretation. As one-time separation outlays fade, a significant portion of recent free cash flow improvement stems from the runoff of temporary separation costs rather than core operational gains. Disentangling these temporary expense roll-offs from ongoing business performance remains critical to evaluating Sandoz's steady-state earnings power.

↑ Back to Top

VI. Segment Economics and the Materiality Breakdown

Evaluating Sandoz requires moving beyond consolidated figures to examine the two distinct operating models within the enterprise.

For full-year 2025, Sandoz reported net sales of $11.1 billion, representing a 5% increase at constant currencies. Generics generated $7.8 billion, or 70% of total revenue, while biosimilars contributed $3.3 billion, or 30%, after growing 13% at constant currencies.²⁸⁴ By the first half of 2026, the product mix shifted further: biosimilars expanded 20% at constant currencies to reach a record $1.875 billion—or 33% of total revenue—while generics contracted 1% at constant currencies to $3.886 billion.⁸²⁹

This shifting revenue distribution encapsulates both the core investment thesis and its primary operational risk.

Segment one: generics, or the business that pays for everything

The generics division spans multiple product formats, including oral solids, oral liquids, complex injectables, ophthalmics, dermatology, and active pharmaceutical ingredients (APIs) sold to third parties as well as consumed internally.

The primary asset within this segment is the manufacturing complex in Kundl, located in the Austrian Tyrol. As Europe's last remaining fully integrated penicillin manufacturing facility, Kundl executes the complete production cycle from fermentation to finished dosage forms. Sandoz remains the sole producer in the European Union of 6-aminopenicillanic acid, the foundational chemical intermediate required for all penicillin antibiotics.³⁰ The site manufactures approximately 4,000 metric tons of amoxicillin annually, supplying the world's most widely prescribed antibiotic.³¹

In 2021, Sandoz committed €150 million to upgrade the site, supported by €50 million from the Austrian federal government under a public initiative to secure European antibiotic supply chains.³² The expanded plant was inaugurated in November 2023 and officially opened in March 2024, expanding Kundl's annual capacity to roughly 240 million packages—a 20% increase over 2023 levels and more than double its 2021 output.³³³¹

The strategic rationale behind the investment is straightforward: government co-financing to mitigate dependency on Asian suppliers effectively elevates a commodity antibiotic facility into critical national infrastructure.

However, financial performance in 2025 and 2026 highlighted the limits of regional supply security. On the full-year 2025 earnings call, management acknowledged that its business-to-business penicillin franchise faced pressure from aggressive pricing by Asian suppliers, warning that the headwinds would continue into the first half of 2026.³⁴ That pressure materialized as projected: generic revenues contracted at constant currencies in the first half of 2026, with equity analysts identifying competition from Chinese penicillin API producers as a primary drag and anticipating further margin pressure in the third quarter.⁵

This dynamic illustrates the difference between policy objectives and commercial execution. While European health authorities emphasize supply chain resilience, public procurement frameworks continue to award contracts primarily on price. Until European tendering regulations formally incorporate premiums for regional manufacturing—a policy concept discussed but not broadly enacted—Kundl's strategic value generates political goodwill rather than immediate gross margin expansion.

Structurally, the generics division generates margins below the group average while serving as the foundational cash generator funding biosimilar R&D and capital projects. Management has maintained its commitment to the core segment, supported by a development pipeline of more than 300 generic assets designed for patent expirations extending through 2036.⁸ Within the broader equity story, the segment's role is to provide stable cash flow while higher-margin products assume a larger share of group revenue.

Segment two: biosimilars, or the reason anyone owns the stock

The biosimilar portfolio represents the primary driver of group margin expansion. Because gross margins on biologic copies far exceed those of traditional generics, the segment accounts for a disproportionate share of overall earnings growth despite generating only a third of group revenue.

First-half 2026 results illustrated this operational leverage. During the earnings call, management attributed approximately 200 basis points of core margin expansion directly to the biosimilar product mix, prior to gains from manufacturing efficiencies or operating leverage.⁸ Driven primarily by new denosumab launches, North American biosimilar sales surged 47% in the first half, lifting total North American net sales 18% to $706 million.²⁹

The commercial roll-out of denosumab demonstrates the dynamics of biosimilar market entry. In March 2024, the FDA approved Wyost and Jubbonti as the first interchangeable biosimilars referencing Amgen's Prolia and Xgeva. Following an April 2024 patent settlement with Amgen authorizing a U.S. launch on or after May 31, 2025, Sandoz brought both products to market on June 2, 2025.³⁵³⁶

Securing first-mover status with an interchangeable biosimilar offers substantial commercial value, as interchangeability allows pharmacy-level substitution without requiring a revised prescription. On the full-year 2025 call, management highlighted strong initial commercial adoption and stable pricing.³⁴ However, competitive entrants arrived swiftly: Samsung Bioepis secured U.S. denosumab approval in February 2025, followed by approvals for Fresenius Kabi and Celltrion in March 2025.³⁶ As a result, Sandoz's initial market exclusivity lasted only months. During the 2025 earnings call, analysts—notably Graham Parry of Bank of America—questioned how long premium pricing could persist as three competing products entered the market.³⁴ Management responded that expanding adoption volume was expected to offset price erosion, a trajectory that will be tested across upcoming reporting periods.

Capital deployment: what management has actually done with the money

Since its separation from Novartis, Sandoz has executed a series of targeted transactions that define its operational priorities.

Cimerli (January–March 2024). In January 2024, Sandoz agreed to acquire the Cimerli ranibizumab biosimilar business from Coherus BioSciences for $170 million upfront in cash, completing the transaction on March 4, 2024.³⁷³⁸ The acquisition provided more than just a marketed biologic; it delivered a complete commercial infrastructure, including a specialized ophthalmology sales team, field reimbursement specialists, and established customer accounts. Securing this commercial footprint positioned Sandoz to efficiently launch subsequent ophthalmology assets, such as its aflibercept biosimilar, through an established distribution channel.

Henlius licensing (April 2025). Sandoz secured exclusive commercialization rights from Shanghai Henlius Biotech for HLX13, a proposed ipilimumab biosimilar referencing Yervoy, covering the United States, 42 European countries, Japan, Canada, and Australia. Under the agreement, Henlius remains responsible for development, manufacturing, and supply, while becoming eligible for milestone payments up to $301 million, including a $31 million upfront fee.³⁹

Just-Evotec Biologics (2025). In its largest post-spin transaction, Sandoz agreed to acquire Just-Evotec Biologics EU SAS, including a state-of-the-art manufacturing facility in Toulouse, France, for approximately $350 million upfront. The deal included an indefinite technology license for Just-Evotec's continuous manufacturing platform across an unlimited number of molecules, with up to 10 assets subject to potential milestone and royalty payments totaling up to $300 million.⁴⁰⁴¹ The transaction closed on December 5, 2025.⁴²

Continuous biomanufacturing fundamentally alters traditional production economics. Standard bioprocessing operates via discrete batches, requiring large bioreactors that run periodically with significant downtime between cycles. Continuous manufacturing maintains an uninterrupted flow through cell culture and purification, enabling higher output from a smaller physical footprint. At commercial scale, this technology reduces both facility capital expenditure and unit manufacturing costs per gram.

In off-patent biologics, unit production costs determine long-term competitiveness. As multiple biosimilars enter the market and prices compress, profitability shifts toward the lowest-cost producer. Acquiring a continuous manufacturing platform serves as a direct investment in long-term cost leadership.

Samsung Bioepis expansion (March 18, 2026). Sandoz expanded its existing partnership with South Korea's Samsung Bioepis, signing a licensing, development, and commercialization agreement covering up to five additional biosimilar candidates.⁴³⁴⁴

Pipeline. By the first half of 2026, Sandoz's combined internal and partnered biosimilar pipeline expanded to 36 assets following four additions during the period—sotatercept, polatuzumab vedotin, burosumab, and anifrolumab—supported by the opening of a dedicated biosimilar development center in Ljubljana, Slovenia.²⁹⁸

What the capital allocation pattern actually says

Collectively, these post-spin transactions reflect greater capital discipline than the large acquisitions executed during the Novartis era. Targeted acquisitions like Cimerli ($170 million) and Just-Evotec ($350 million upfront) represent manageable bolt-on investments rather than large-scale, peak-cycle consolidations. Balance-sheet leverage remains controlled, with net debt ending 2025 at $3.6 billion, equivalent to 1.5 times core EBITDA.⁴

The primary financial constraint remains elevated capital expenditure. Capex reached approximately $700 million in 2025 and was projected to peak at around $1.1 billion in 2026, driven by investments in the Slovenian biosimilar development hub, with first-half spending reaching nearly €500 million.³⁴⁸ This investment represents nearly 10% of annual revenue. Management has framed 2026 as the peak investment year necessary to support upcoming product launches. The validity of this projection will depend on whether capital outlays decline significantly in 2027 to allow expected free cash flow expansion.

This capital trajectory focuses attention directly on executive management and operational execution.

↑ Back to Top

VII. Executive Leadership, Governance, and Management Credibility

In the pharmaceutical industry, executive leadership often splits between high-profile innovators pursuing novel blockbusters and operational specialists who manage mature, off-patent portfolios. CEO Richard Saynor exemplifies the latter category, bringing an operational background well aligned with the task he inherited upon taking leadership of Sandoz in 2019.

Richard Saynor

Before joining Sandoz, Saynor led GlaxoSmithKline's Classic and Established Products division—the unit responsible for maximizing value from off-patent medicines—following senior executive roles at Teva. He arrived at Sandoz shortly after Novartis failed to divest its U.S. generic oral solids and dermatology business, inheriting a division in need of structural operational repositioning.

Saynor's operating signature reflects three distinct characteristics visible in the corporate record.

First, an unsentimental approach to top-line volume. While generic executives with growth mandates typically defend market share, Saynor pruned unprofitable product lines and accepted revenue declines in commodity categories to preserve gross margins.

Second, a willingness to address structural industry headwinds directly. On the full-year 2025 earnings call in February 2026, management did not frame weakness in the penicillin business-to-business franchise as a temporary fluctuation; instead, leadership cited Asian price competition, highlighted the risk of Indian import rules diverting low-cost supply into Europe, and advocated for European policy reforms.³⁴ Directly identifying structural pressure differs from the conventional corporate approach of attributing operational misses to short-term timing.

Third, a deliberate emphasis on institutional milestones. Saynor opened the full-year 2025 call by highlighting a series of corporate anniversaries—twenty years of biosimilars, eighty years of penicillin production in Kundl, and 140 years of Sandoz history.³⁴ Highlighting these milestones reflects an effort to reframe an inherited industrial footprint into a distinct corporate identity.

The CFO transition

Colin Bond managed the initial phase of corporate independence, establishing the standalone finance function, drafting the prospectus, overseeing the SIX listing, and guiding early reporting cycles. Following his decision to retire, Sandoz announced its executive succession plan on March 5, 2024.⁴⁵

His successor represented an unconventional appointment. Remco Steenbergen was already serving on the Sandoz board of directors; he stepped down from the board—declining to seek re-election at the April 30, 2024 annual general meeting—and assumed the CFO role on July 1, 2024.⁴⁵ Steenbergen previously served as group CFO at Deutsche Lufthansa AG during its pandemic-era balance sheet restructuring, after holding the CFO role at Swiss cocoa processor Barry Callebaut AG.

Neither background originated in pharmaceuticals, which aligns with Sandoz's operational requirements. Lufthansa provided experience in balance-sheet management under strict solvency pressures, while Barry Callebaut operates as a high-volume, low-margin industrial processor where working capital discipline and raw-material cost pass-through dictate profitability—dynamics closely matching generic drug manufacturing. Selecting an existing board member eliminated the strategic learning curve, though it also meant prioritizing internal continuity over an outside perspective.

Steenbergen's financial communication has emphasized specific operational milestones. On the first-half 2026 earnings call, he stated that second-half growth would outpace first-half performance and that fourth-quarter sales would exceed third-quarter results—providing explicit metrics against which investors can measure execution.⁸

The chairman and the board

Gilbert Ghostine serves as chairman of the board. He previously served as chief executive of Swiss flavor and fragrance manufacturer Firmenich following a long career at Diageo. Firmenich offers a relevant operational parallel: a Swiss business-to-business supplier competing on formulation chemistry, manufacturing reliability, and multi-year customer relationships rather than consumer branding—structurally similar to supplying off-patent biologics to healthcare systems and purchasing alliances.

The board of directors has been restructured to support biosimilar expansion rather than traditional generic manufacturing. The 2024 director nominations included Mathai Mammen, a physician-scientist and former head of research and development at Johnson & Johnson's pharmaceutical division, alongside Michael Rechsteiner.⁴⁵ Adding senior scientific leadership to the board strengthens oversight of complex biologic development programs.

The credibility scorecard

Evaluating management credibility requires comparing initial targets against disclosed performance.

At the time of the spin-off, leadership established mid-term targets through 2028 of mid-single-digit constant-currency sales growth and a core EBITDA margin between 24% and 26%.⁶ Operational execution has aligned with this trajectory: core EBITDA margin expanded from 18.1% in 2023 to 20.1% in 2024 and 21.7% in 2025.⁴⁷ The 2025 result represented a 160-basis-point improvement. Management guided to roughly 100 basis points of additional expansion for 2026, delivering 90 basis points in the first half.⁸ Leadership reiterated the 24% to 26% margin target during the first-half 2026 earnings call without adjustment.⁸

Narrative continuity has matched financial execution. Management's strategic message in early 2026 mirrored its spin-off presentation: biosimilar mix expansion drives margin improvement, one-time separation expenses decline on schedule, capital expenditure peaks before moderating, and traditional generics generate steady cash flow despite top-line contraction. The company has maintained its stated core objectives without unexpected strategic shifts.

However, two key factors warrant scrutiny.

First, initial margin expansion benefited significantly from the burn-off of legacy separation expenses and product-line rationalization. Because these represent one-time adjustments, subsequent gains toward the 2028 target must originate from organic operating leverage and favorable product mix, which present higher execution hurdles.

Second, during the first half of 2026, management revised its full-year net price erosion expectation from low-to-mid single digits to mid-single digits while keeping full-year sales and margin targets unchanged.⁵ While management argued that expanding volume and favorable biosimilar mix would offset pricing pressure, accelerating price deflation compresses financial flexibility if volume growth decelerates. Steenbergen noted on the earnings call that higher sales volumes naturally attract steeper price reductions—a candid assessment that nevertheless highlights ongoing market pressure.

This shift in price erosion guidance underscores changing market dynamics, as Sandoz faces growing competition from emerging biosimilar producers.

↑ Back to Top

VIII. Structural Moats and Competitive Dynamics

When Omnitrope received European approval in 2006, Sandoz faced virtually no established biosimilar competitors. By 2026, agile South Korean firms have emerged as the fastest-moving players in global biosimilars, capturing leading market positions across major therapeutic categories. This shift underlines the evolving competitive dynamics surrounding Sandoz's business model.

Seven Powers: what actually protects this business

Applying Hamilton Helmer's 7 Powers framework to Sandoz highlights two distinct strategic advantages, one moderate power, and several notable omissions.

Scale economies — strong in development, but narrow in manufacturing. Biosimilar economics reward global reach in product development. Because analytical characterization and clinical trials represent fixed costs, developing a biosimilar costs roughly the same regardless of geographic scope. Sandoz amortizes its development outlays across an extensive commercial footprint spanning Europe, North America, and emerging markets, reducing its breakeven threshold per territory. This global amortization capacity represents one of the strongest structural pillars of the business.

However, scale in small-molecule manufacturing—a historic core strength for Sandoz—provides minimal pricing protection. As demonstrated by the U.S. generics price collapse and ongoing pressure on European penicillin intermediates, factory scale fails to insulate commodity products from aggressive price erosion.

Process power — established and expanding. Decades of specialized experience in mammalian cell culture across Austrian and German manufacturing facilities cannot be easily replicated. Bioprocessing yield optimization relies heavily on tacit operational expertise built over numerous production cycles. The acquisition of Just-Evotec Biologics represents an effort to reinforce this position by integrating continuous manufacturing capabilities. Whether this technology converts into a durable cost advantage will depend on execution in scaling production.

Cornered resource — moderate and eroding. Regulatory experience and an established portfolio of launched biosimilars represent valuable operational assets. However, competing manufacturers have secured comparable FDA and EMA approvals over the past decade. Early regulatory pioneering functions as a temporary head start rather than an exclusive structural asset once regulatory pathways are broadly established.

Counter-positioning — moderate and constrained. Proponents argue that originator pharmaceutical companies cannot aggressively discount legacy biologics without cannibalizing prices on next-generation therapies or altering existing payer contracts. While this dynamic creates initial commercial space, the market introduction of biosimilar adalimumab demonstrated that originators and pharmacy benefit managers can employ alternative contracting strategies that bypass direct price discounting.

Absent: network economies, switching costs, and brand equity. Biosimilar commercialization features no meaningful network effects. Regulators intentionally design substitution mechanisms at the payer and pharmacy levels to minimize switching costs. While brand reputation provides a modest trust factor with prescribing physicians, it functions as a tiebreaker rather than a defensible barrier.

Porter's five forces: where the pressure comes from

Buyer power — the dominant industry force in the United States. Three major pharmacy benefit managers—CVS Caremark, Express Scripts, and OptumRx—control approximately 80% of prescriptions dispensed in the United States.⁴⁶ These intermediaries act as gatekeepers, determining formulary access and commercial viability for off-patent biologics.

The U.S. launch of biosimilar adalimumab illustrates the impact of buyer concentration. Until April 2024, biosimilar adalimumab adoption in the United States remained stalled at 2% to 3% of the market despite multiple approved options, as major benefit managers retained reference drug Humira on their formularies.⁴⁶ When CVS Health shifted policy, it excluded Humira in favor of three alternatives: Sandoz's branded Hyrimoz, a private-label version of Hyrimoz distributed by CVS subsidiary Cordavis, and an unbranded private-label Humira also distributed by Cordavis.⁴⁶

Prescription volumes shifted rapidly. The Cordavis private-label products secured 15% of overall adalimumab market share within two months, and by August 2024 CVS had transitioned 97% of Humira volume among its commercial customers to biosimilars.⁴⁶ However, the distribution of market share highlighted where economic control resided: Cordavis private-label Hyrimoz captured 11% and private-label unbranded Humira took 5%, while Sandoz's own branded Hyrimoz held 4%, leaving nine other manufacturers to divide the remaining 9%.⁴⁶

This outcome demonstrates the structural reach of buyer power. While Sandoz supplied the underlying product, the majority of market share accumulated under the benefit manager's private label on terms negotiated by the intermediary. In highly concentrated buyer markets, manufacturers risk operating as contract suppliers while intermediaries capture customer alignment and commercial margin.

Threat of new entrants — low in biosimilars, high in traditional generics. High development costs exceeding $100 million alongside complex patent litigation limit the global biosimilar field to roughly a dozen major producers. Conversely, low regulatory and capital barriers in oral solid generics enable widespread entry, sustaining intense price competition in commodity markets.

Supplier power and substitutes — generally moderate, with targeted pressure. Upstream supply risks remain concentrated in key raw materials and active pharmaceutical ingredients. As seen in the European penicillin market, maintaining regional manufacturing capacity offers limited protection when foreign producers price chemical intermediates aggressively.

Competitive rivalry — intensifying through Asian market entrants.

셀트리オン Celltrion, a vertically integrated South Korean biosimilar developer, conducts in-house manufacturing, clinical development, and direct commercialization. The company has expanded rapidly, reporting second-quarter 2026 revenue growth of approximately 45% year over year and an 86% increase in operating profit.⁴⁷

삼성바이오로직스 Samsung Biologics and its affiliate Samsung Bioepis pair large-scale contract biomanufacturing with rapid clinical development. Bioepis holds the largest European market share in etanercept and has consistently outpaced incumbent producers across antibody biosimilars.[^48]

Together, these two South Korean companies held a combined 53.5% share of Europe's six largest biosimilar molecule categories as of late 2024—spanning infliximab, rituximab, adalimumab, trastuzumab, bevacizumab, and etanercept.[^49] In infliximab specifically, South Korean manufacturers captured 84.2% of the European market.[^49]

This market penetration reflects a shift in a category Sandoz originally pioneered in Europe. Sandoz has responded by partnering with Samsung Bioepis to commercialize products such as Pyzchiva and collaborate on additional pipeline assets. While partnering leverages Sandoz's commercial distribution network while capitalizing on Bioepis's development pace, distributing a competitor's molecule yields commercial distribution margins rather than manufacturing profits, creating long-term reliance on external development partners.

Teva Pharmaceutical Industries and Viatris remain substantial global competitors while continuing to address legacy debt and portfolio restructuring. Amgen operates across both originator biologics and biosimilars, balancing portfolio expansion against its innovator business. Fresenius Kabi maintains a strong European presence in oncology and immunology biosimilars, introducing its denosumab biosimilars shortly after Sandoz's launch. 复宏汉霖 Shanghai Henlius Biotech operates as both a commercial partner to Sandoz on ipilimumab and a competitor in other therapeutic areas.

Sandoz's biosimilar moat remains operational but narrow. Its primary competitive advantage relies less on scientific speed—where South Korean developers demonstrate faster execution—and more on global commercial reach, established regulatory capabilities, and long-term manufacturing cost efficiency.

↑ Back to Top

IX. Bull vs. Bear Case, Risk Radar, and Primary KPIs

The core investment decision around Sandoz hinges on a single testable premise: whether product mix expansion toward biosimilars can outpace price erosion in traditional generics long enough to reach management's 2028 margin targets.

The bull case

First, margin expansion is already evident in reported financial results. Three consecutive years of core EBITDA margin expansion—rising from 18.1% in 2023 to 20.1% in 2024 and 21.7% in 2025, followed by 90 basis points of expansion in the first half of 2026—demonstrate an operational track record rather than a theoretical projection.⁴⁷⁸ The underlying mechanism is straightforward: biosimilars generate structurally higher gross margins and are growing four to five times faster than the rest of the business, with management attributing roughly 200 basis points of first-half margin expansion directly to biosimilar mix. Over the same six-month period, core diluted earnings per share increased 17% to $1.71, while full-year 2025 free cash flow expanded by $435 million to reach $1.5 billion, confirming that reported accounting gains are converting into cash.²⁹⁴

Second, commercial launch momentum is supported by a broad development pipeline. Sandoz maintains 36 biosimilar assets—adding four in the first half of 2026 alone—alongside more than 300 generic pipeline projects targeting patent expirations through 2036.⁸ Near-term commercial roll-outs, including denosumab in the United States and Europe, aflibercept in Europe, and ustekinumab across both regions, are already generating revenue, driving a 47% surge in North American biosimilar sales in the first half of 2026.²⁹ The company also holds optionality in GLP-1 therapeutics: Brazilian regulator Anvisa approved the generic semaglutide product Owozy—developed by Adalvo and marketed by Sandoz in Brazil—for a second-half 2026 launch, while the U.S. FDA accepted two abbreviated new drug applications for generic tirzepatide in June 2026.⁴⁸⁴⁹ However, because core U.S. patents on tirzepatide extend to 2036, the FDA filing represents long-term strategic positioning rather than a near-term revenue catalyst.⁴⁹

Third, corporate separation costs are winding down on schedule. One-time separation outlays have steadily declined over three consecutive years, leaving net debt at 1.5 times core EBITDA and preserving balance-sheet flexibility.⁴ Management signaled confidence in ongoing cash generation by expanding the 2025 dividend by one-third to CHF 0.80 per share during a period of peak capital expenditure.³⁴

The bear case, argued properly

First, U.S. pharmacy benefit manager rebate structures represent a persistent market constraint rather than a temporary hurdle. Commercial adoption of Hyrimoz illustrates the structural limitations facing biosimilar producers. Despite securing preferred formulary status with the largest U.S. benefit manager, branded Hyrimoz captured only a 4% market share, while the benefit manager's private-label version secured 11%.⁴⁶ As major PBMs expand private-label distribution, biosimilar manufacturers risk being reduced to low-margin contract suppliers, a position that historically cannot sustain 24% to 26% EBITDA margins.

Second, peak capital expenditure of $1.1 billion places heavy reliance on 2027 cash flow execution. With roughly 10% of annual revenue allocated to capital projects in 2026, the free cash flow trajectory depends on spending moderating as projected.³⁴⁸ Construction overruns at the Slovenian development hub, higher-than-expected integration costs for Just-Evotec in Toulouse, or expanded manufacturing requirements across the biosimilar pipeline could compress cash flow before margin targets are realized.

Third, South Korean biosimilar developers maintain operational speed and cost advantages. European market share data across major biologic categories demonstrates the rapid expansion of Asian entrants.[^49] While licensing agreements with partners like Samsung Bioepis secure market access, commercializing third-party molecules caps Sandoz's margin capture and creates ongoing reliance on external R&D platforms. Concurrently, competitors like Celltrion continue to expand direct commercialization capabilities.

Fourth, the traditional generics division is contracting rather than stabilizing. Constant-currency generic revenues declined 1% in the first half of 2026.²⁹ The bull thesis relies on generics serving as a steady cash engine to fund biosimilar expansion. If the legacy division contracts while continuing to require maintenance capital, generating group margin expansion becomes mathematically more difficult, as a contracting unit representing two-thirds of group revenue presents a substantial drag on the smaller, growing biosimilar segment.

The activist stress test

A critical analysis of management's execution highlights four key operational questions.

The first involves guidance asymmetry. During the first half of 2026, management raised its full-year price erosion expectation from low-to-mid single digits to mid-single digits while holding sales and margin targets unchanged.⁵ Maintaining full-year guidance under accelerating price deflation assumes that sales volumes and product mix will overperform, leaving little room for operational disruption.

The second concerns portfolio complexity. Sandoz operates across oral solids, complex injectables, dermatology, ophthalmology, anti-infectives, third-party active pharmaceutical ingredients, and biosimilars across a broad global manufacturing network. Each product line requires distinct regulatory, quality, and commercial infrastructure. Management maintains that this broad network ensures supply chain security and fixed-cost absorption, but retaining a long tail of low-margin legacy generic assets absorbs capital and executive focus that could otherwise be directed to higher-margin biologics.

The third centers on partnership transparency. Financial disclosures do not break out the precise share of biosimilar revenue and margin generated by in-licensed assets compared to internally developed molecules. Because key pipeline assets—including Pyzchiva, Epysqli in select markets, and licensed candidates from Henlius and Samsung Bioepis—rely on external partners, this disclosure gap conceals the true margin profile. In-licensed therapeutics generally yield lower gross margins and less durable competitive protection than wholly owned assets.

The fourth focuses on accountability within the penicillin active pharmaceutical ingredient business, which has missed internal expectations across two consecutive reporting cycles due to pricing pressure from Asian suppliers.³⁴⁵ Repeated operational misses attributed to the same external factor suggest structural competitive impairment rather than a short-term cyclical swing.

The current risk radar

Trade and tariff policy represents the most immediate emerging operational risk. In July 2026, the U.S. administration announced a tariff schedule on imported generic pharmaceuticals: a two-year 0% tariff window beginning August 1, 2026, followed by a 100% tariff in year three and 200% thereafter, intended to force reshoring of drug production.⁵⁰⁵¹ Equity markets reacted promptly, sending Sandoz shares down as much as 4.2%.⁵² Because Sandoz's manufacturing footprint remains heavily concentrated in Europe—spanning Austria, Germany, Slovenia, and France—supplying its U.S. generic business under a 100% tariff presents a severe operational challenge. The two-year grace period creates a narrow window to adjust supply chains, conflicting directly with a capital investment plan built around European facilities rather than U.S. capacity.

Regulatory and legislative dynamics in the United States present additional complexity. Price negotiation provisions under the Inflation Reduction Act alter how brand-name manufacturers manage product lifecycles. Lowering originator prices may shorten the window of high-margin biosimilar opportunity, while shifting payer incentives could compress the pricing umbrella under which biosimilars debut.

Biologics manufacturing execution carries high operational downside. Contamination incidents or FDA regulatory sanctions at biomanufacturing facilities can suspend commercial supply for extended periods. For an enterprise relying on a concentrated pipeline of biosimilar launches to drive group profitability, a major quality disruption at a key facility would directly impair financial performance.

Supply chain concentration remains evident in intermediate inputs, specifically European reliance on Asian chemical suppliers for foundational active ingredients.³⁴

Transformation execution risk reflects a broader historical baseline. Spinoffs targeting multi-year margin expansion frequently deliver initial gains through immediate efficiency measures, but face difficulty sustaining margin momentum as cost-cutting opportunities diminish.

The three KPIs that matter

Evaluating Sandoz's operational trajectory requires monitoring three key performance indicators.

First, biosimilar revenue growth and segment mix shift. This metric reflects the core thesis in a single ratio. Biosimilars expanded from 30% of net sales in 2025 to 33% in the first half of 2026 and 34% in the second quarter.⁴²⁹ Sustaining double-digit constant-currency growth and pushing biosimilars toward a larger share of revenue remains essential to reaching group margin targets. Conversely, a plateau caused by PBM private-label expansion, Asian price competition, or launch delays would prevent management from meeting its 2028 projections.

Second, core EBITDA margin trajectory against medium-term targets. Management has targeted a 24% to 26% core EBITDA margin by 2028.⁶⁸ Moving from 21.7% at year-end 2025 requires consistent annual expansion of roughly 100 basis points as one-time separation benefits fade, making each reporting period a direct measure of underlying operational leverage.

Third, free cash flow conversion. Management free cash flow reached $1.5 billion in 2025.⁴ Evaluating cash performance following the 2026 capital expenditure peak will determine whether reported margin gains reflect genuine economic profitability or working capital and accounting adjustments.

↑ Back to Top

X. Playbook: Business and Investing Lessons

The Sandoz trajectory yields three durable strategic and investment lessons that extend well beyond the pharmaceutical industry.

Corporate carve-outs work because capital gets repriced, not because management gets better. The executive team running Sandoz after its October 2023 spin-off remained largely identical to the team that managed it within Novartis. What shifted was the opportunity cost of capital. Within Novartis, an incremental dollar allocated to biosimilar development competed against higher-margin blockbusters like Cosentyx and lost. Within an independent Sandoz, that same dollar competes against share repurchases or debt reduction—and clears corporate hurdle rates far more easily. Core EBITDA margin expanded from 18.1% to 21.7% in two years without altering the underlying science.⁴ For investors, the takeaway is to identify corporate divisions whose high-return opportunities are rationally starved by even higher-margin priorities elsewhere in a conglomerate. The latent value resides not in hidden operational efficiencies, but in the capital allocation hierarchy that constrained it.

The corollary is equally important: trapped value is finite and releases rapidly. Once low-hanging cost rationalization is complete and corporate separation expenses run off, the enterprise must generate incremental returns through ordinary operational execution. Investors who extrapolate the initial margin expansion of a carve-out into perpetuity risk mistaking a one-time structural re-rating for permanent momentum.

Climbing the complexity curve is the primary defense against commodity deflation. The collapse in U.S. generic drug pricing was not a temporary cyclical downturn, but a structural shift driven by buyer consolidation. Once a customer base concentrates into three dominant purchasing consortiums and products become legally certified bioequivalent commodities, pricing power cannot be restored through manufacturing scale alone. The only strategic defense is migrating toward complex product categories where technical, clinical, and regulatory hurdles limit competitive entry.

Sandoz executed this transition by expanding from small-molecule generics that cost single-digit millions to copy into complex biologics requiring hundreds of millions in development capital. While effective, the rapid rise of agile South Korean competitors demonstrates that technical complexity provides temporary breathing room rather than permanent insulation. Capable rivals inevitably scale the same curve. Sustained competitiveness requires continuous advancement, making structural cost investments—such as the acquisition of Just-Evotec's continuous manufacturing platform—more strategically decisive over the long term than any single biosimilar launch.

Sovereign industrial relevance is real optionality, but it is not yet cash flow. Kundl's position as Europe's last integrated penicillin producer and the only EU manufacturer of 6-APA gives Sandoz something no competitor has: a seat at the table when European governments discuss pharmaceutical supply security, and a legitimate claim on public co-investment.³⁰³²

However, penicillin financial performance in 2025 and 2026 illustrates the gap between geopolitical salience and commercial reality. European procurement frameworks have not yet been restructured to award pricing premiums for regional manufacturing, leaving buyers to purchase the lowest-cost intermediates supplied primarily from Asia. For investors, strategic industrial assets function more like real options than fixed annuities—yielding value if government tendering policies shift, but operating as capital-intensive facilities until then. Sandoz's shareholders effectively hold a call option on European industrial policy: potentially valuable over the long term, but not yet monetized.

↑ Back to Top

XI. Epilogue and What to Watch

On the morning of August 5, 2026, Sandoz reported that biosimilars had reached a record 33% of net sales, that its pipeline had expanded to 36 assets, and that management was maintaining full-year guidance despite accelerating price erosion.²⁹⁸ Intraday, the shares rose as much as 8.1%.⁵ Equity research opinion remained sharply divided: Jefferies maintained a Buy rating with a CHF 82 price target, while Morgan Stanley held an Underweight rating at CHF 55—a wide valuation spread signaling that Wall Street has not yet reached a consensus on the company's steady-state identity.⁵

That divergence reflects the current state of the Sandoz narrative. The company is roughly halfway through a multi-year restructuring announced at its spin-off and executed on schedule thus far. The second half, however, presents steeper operational hurdles: early cost-cutting and separation-expense tailwinds are diminishing, capital expenditure is reaching its peak, major U.S. biosimilar opportunities remain concentrated under three powerful purchasing intermediaries, and low-cost South Korean competitors continue to execute with greater speed.

Sandoz counters these challenges with a 140-year manufacturing heritage across Basel, Kundl, Schaftenau, Holzkirchen, Ljubljana, and Toulouse, a global commercial footprint spanning more than 100 markets, and the institutional experience of pioneering biosimilar regulatory approvals in Europe and the United States. Whether these assets constitute a durable competitive moat or merely a temporary head start will be tested over the next two years.

Three key factors warrant close attention:

The commercial trajectory of recent biosimilar launches. First-mover pricing advantages for denosumab face three established competitors in the market, while roll-outs for ustekinumab and aflibercept remain in early stages. The rate of price erosion across these products will serve as the clearest real-time test of whether biosimilar economics can withstand competition better than traditional generics—the core assumption underlying management's margin targets.

Whether capital expenditure declines after 2026. Management has identified 2026 as the peak investment year.³⁴ Disclosed capex figures for 2027 will confirm whether spending moderates as projected, determining whether core margin expansion translates into sustained free cash flow growth.

How U.S. trade policy evolves. With a 100% tariff scheduled to take effect in August 2028 and 200% thereafter, a producer reliant on European manufacturing facilities to supply a substantial U.S. business has roughly two years to reconfigure supply chains, absorb higher costs, adjust pricing, or exit specific product lines.⁵⁰ Each option carries significant financial and operational implications. Trade policy represents the largest external variable in Sandoz's outlook—and one over which management has no direct control.

Sandoz Group AG

Table of Contents

Sandoz Group AG: The Off-Patent Biopharmaceutical Giant's Independence Play

I. Introduction & The Sandoz Paradox

II. Origins: Dye Stuffs, Ergot Alkaloids, and the LSD Epoch (1886–1996)

III. The Novartis Era: Building a Generic Roll-Up and the M&A Trap (1996–2017)

The roll-up years

What the deals actually bought

The conglomerate subsidy trap

IV. The Generic Price Cliff and the Failed Aurobindo Fire Sale (2018–2020)

The exit that wasn't

The consolation prize

V. The Great Pivot: Pioneering Biosimilars and the October 2023 Spin-Off

Sandoz got there first, twice

The patent cliff that made it worth doing

The separation

The umbilical cord

VI. Segment Economics and the Materiality Breakdown

Segment one: generics, or the business that pays for everything

Segment two: biosimilars, or the reason anyone owns the stock

Capital deployment: what management has actually done with the money

What the capital allocation pattern actually says

VII. Executive Leadership, Governance, and Management Credibility

Richard Saynor

The CFO transition

The chairman and the board

The credibility scorecard

VIII. Structural Moats and Competitive Dynamics

Seven Powers: what actually protects this business

Porter's five forces: where the pressure comes from

IX. Bull vs. Bear Case, Risk Radar, and Primary KPIs

The bull case

The bear case, argued properly

The activist stress test

The current risk radar

The three KPIs that matter

X. Playbook: Business and Investing Lessons

XI. Epilogue and What to Watch

References